Emergent BioSolutions Inc.
EBS
$8.07
-$0.06-0.74%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 742.90M | 788.90M | 851.60M | 965.40M | 1.04B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 742.90M | 788.90M | 851.60M | 965.40M | 1.04B |
| Cost of Revenue | 376.00M | 405.00M | 435.60M | 675.60M | 732.40M |
| Gross Profit | 366.90M | 383.90M | 416.00M | 289.80M | 311.20M |
| SG&A Expenses | 186.60M | 195.70M | 233.30M | 266.60M | 298.70M |
| Depreciation & Amortization | 65.10M | 65.10M | 65.10M | 65.20M | 65.10M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 627.30M | 665.00M | 733.00M | 1.01B | 1.10B |
| Operating Income | 115.60M | 123.90M | 118.60M | -41.00M | -51.60M |
| Income Before Tax | 82.80M | 105.90M | 190.70M | -62.30M | -142.90M |
| Income Tax Expenses | 30.20M | 30.00M | 51.20M | 69.30M | 47.70M |
| Earnings from Continuing Operations | 52.60 | 75.90 | 139.50 | -131.60 | -190.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.60M | 75.90M | 139.50M | -131.60M | -190.60M |
| EBIT | 115.60M | 123.90M | 118.60M | -41.00M | -51.60M |
| EBITDA | 208.90M | 220.00M | 217.40M | 62.40M | 54.00M |
| EPS Basic | 0.95 | 1.41 | 2.61 | -2.55 | -3.63 |
| Normalized Basic EPS | 1.18 | 1.34 | 1.66 | -0.34 | -1.31 |
| EPS Diluted | 0.84 | 1.30 | 2.45 | -2.71 | -3.73 |
| Normalized Diluted EPS | 1.07 | 1.23 | 1.55 | -0.45 | -1.36 |
| Average Basic Shares Outstanding | 214.20M | 216.00M | 215.90M | 214.30M | 212.10M |
| Average Diluted Shares Outstanding | 220.40M | 222.20M | 221.30M | 219.70M | 214.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |